Company / R&D per Share
Tandem Diabetes Care R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.91
FY2025
5-year range
$0.73 / $3.03
FY2021-FY2025
Trend
-3.9%
vs FY2024
Sector context
#24 of 108
Health Care
What the data says
Tandem Diabetes Care's r&d per share of $2.91 is higher than 78% of companies in the Health Care sector (FY2025). R&D per Share has fluctuated over the past 10 years, ranging from $0.36 in FY2019 to $5.45 in FY2017.
Based on SEC 10-K filings.
2.91 in FY2025 with a 5-year CAGR of +42.7%. Top quartile in the Health Care sector.
Improved from $2.63 to $2.91 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +43.0%
- 5-Year CAGR
- +42.7%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 108This company $2.91 Sector average $2.07
▼
+40.8% above sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 3.9% year-over-year.
- Ranks #24 out of 108 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2017.
- Lowest r&d per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.91 | -3.9% |
| FY2024 | $3.03 | +15.4% |
| FY2023 | $2.63 | +164.1% |
| FY2022 | $1.00 | +37.4% |
| FY2021 | $0.73 | +47.4% |
| FY2020 | $0.49 | +37.1% |
| FY2019 | $0.36 | -80.7% |
| FY2018 | $1.86 | -65.9% |
| FY2017 | $5.45 | +777.4% |
| FY2016 | $0.62 | -13.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026